BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Lelie D, Taghavi S. COVID-19 and the Gut Microbiome: More than a Gut Feeling. mSystems. 2020;5. [PMID: 32694127 DOI: 10.1128/msystems.00453-20] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Ralli T, Saifi Z, Rathee A, Aeri V, Kohli K. Decoding the bidirectional relationship between gut microbiota and COVID-19. Heliyon 2023;9:e13801. [PMID: 36811017 DOI: 10.1016/j.heliyon.2023.e13801] [Reference Citation Analysis]
2 Iesanu MI, Zahiu CDM, Dogaru I, Chitimus DM, Pircalabioru GG, Voiculescu SE, Isac S, Galos F, Pavel B, O’mahony SM, Zagrean A. Melatonin–Microbiome Two-Sided Interaction in Dysbiosis-Associated Conditions. Antioxidants 2022;11:2244. [DOI: 10.3390/antiox11112244] [Reference Citation Analysis]
3 Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar Jalali H, Shenagari M, Mansour-ghanaei F. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microbial Pathogenesis 2022. [DOI: 10.1016/j.micpath.2022.105704] [Reference Citation Analysis]
4 Badi SA, Khatami S, Siadat SD. Tripartite communication in COVID-19 infection: SARS-CoV-2 pathogenesis, gut microbiota and ACE2. Future Virology. [DOI: 10.2217/fvl-2021-0231] [Reference Citation Analysis]
5 Kumari R, Yadav Y, Misra R, Das U, Das Adhikari U, Malakar P, Dubey GP. Emerging frontiers of antibiotics use and their impacts on the human gut microbiome. Microbiol Res 2022;263:127127. [PMID: 35914416 DOI: 10.1016/j.micres.2022.127127] [Reference Citation Analysis]
6 Chakraborty C, Sharma AR, Bhattacharya M, Dhama K, Lee SS. Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity. World J Gastroenterol 2022; 28(25): 2802-2822 [DOI: 10.3748/wjg.v28.i25.2802] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Mousa WK, Chehadeh F, Husband S. Recent Advances in Understanding the Structure and Function of the Human Microbiome. Front Microbiol 2022;13:825338. [DOI: 10.3389/fmicb.2022.825338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
8 Farsi Y, Tahvildari A, Arbabi M, Vazife F, Sechi LA, Shahidi Bonjar AH, Jamshidi P, Nasiri MJ, Mirsaeidi M. Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review. Front Cell Infect Microbiol 2022;12:804644. [PMID: 35310853 DOI: 10.3389/fcimb.2022.804644] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
9 Ventero MP, Moreno-Perez O, Molina-Pardines C, Paytuví-Gallart A, Boix V, Escribano I, Galan I, González-delaAleja P, López-Pérez M, Sánchez-Martínez R, Merino E, Rodríguez JC. Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area. J Infect 2021:S0163-4453(21)00647-2. [PMID: 34963638 DOI: 10.1016/j.jinf.2021.12.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Singla RK, He X, Chopra H, Tsagkaris C, Shen L, Kamal MA, Shen B. Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources. Front Pharmacol 2021;12:758159. [PMID: 34925017 DOI: 10.3389/fphar.2021.758159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
11 Roy K, Agarwal S, Banerjee R, Paul MK, Purbey PK. COVID-19 and gut immunomodulation. World J Gastroenterol 2021; 27(46): 7925-7942 [DOI: 10.3748/wjg.v27.i46.7925] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
12 Li Z, Li Y, Li L, Mo X, Li S, Xie M, Zhan Y, Lin Y, Li Z, Xie M, Chen Z, Zhu A, Ying R, Yu L, Zhao J, Li SC, Cai W, Ye F. Alteration of the respiratory microbiome in COVID-19 patients with different severities. J Genet Genomics 2021:S1673-8527(21)00344-1. [PMID: 34798357 DOI: 10.1016/j.jgg.2021.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ventero MP, Moreno-perez O, Molina-pardines C, Paytuví-gallart A, Boix V, Galan I, González-delaaleja P, López-pérez M, Sánchez-martínez R, Merino E, Rodríguez JC. Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients: a retrospective cohort study in a Mediterranean area.. [DOI: 10.1101/2021.09.28.461924] [Reference Citation Analysis]
14 Skrajnowska D, Brumer M, Kankowska S, Matysek M, Miazio N, Bobrowska-Korczak B. Covid 19: Diet Composition and Health. Nutrients 2021;13:2980. [PMID: 34578858 DOI: 10.3390/nu13092980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 van der Lelie D, Oka A, Taghavi S, Umeno J, Fan TJ, Merrell KE, Watson SD, Ouellette L, Liu B, Awoniyi M, Lai Y, Chi L, Lu K, Henry CS, Sartor RB. Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nat Commun 2021;12:3105. [PMID: 34050144 DOI: 10.1038/s41467-021-23460-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
16 Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg 2021:trab042. [PMID: 33728439 DOI: 10.1093/trstmh/trab042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]
17 Chhibber-Goel J, Gopinathan S, Sharma A. Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections? Gut Pathog 2021;13:14. [PMID: 33632296 DOI: 10.1186/s13099-021-00407-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
18 Devaux CA, Lagier JC, Raoult D. New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. Front Med (Lausanne) 2021;8:640073. [PMID: 33681266 DOI: 10.3389/fmed.2021.640073] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
19 Dolatshahi M, Sabahi M, Aarabi MH. Pathophysiological Clues to How the Emergent SARS-CoV-2 Can Potentially Increase the Susceptibility to Neurodegeneration. Mol Neurobiol 2021;58:2379-94. [PMID: 33417221 DOI: 10.1007/s12035-020-02236-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
20 Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. World J Clin Cases 2021; 9(1): 8-23 [PMID: 33511168 DOI: 10.12998/wjcc.v9.i1.8] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
21 Ferreira C, Viana SD, Reis F. Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update. Microorganisms 2020;9:E53. [PMID: 33379162 DOI: 10.3390/microorganisms9010053] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
22 Microbiome Centers Consortium COVID Committee . Coordinating and Assisting Research at the SARS-CoV-2/Microbiome Nexus. mSystems 2020;5:e00999-20. [PMID: 33262241 DOI: 10.1128/mSystems.00999-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Mantziari A, Salminen S, Szajewska H, Malagón-Rojas JN. Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases. Microorganisms 2020;8:E1510. [PMID: 33008065 DOI: 10.3390/microorganisms8101510] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]